These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
8. Evaluating negative-symptom-like behavioural changes in developmental models of schizophrenia. Moser P Eur Neuropsychopharmacol; 2014 May; 24(5):774-87. PubMed ID: 24332891 [TBL] [Abstract][Full Text] [Related]
9. [Incidence of the deficit form in refractory schizophrenia]. Samuelian JC Encephale; 1996 Jun; 22 Spec No 2():19-23. PubMed ID: 8767037 [TBL] [Abstract][Full Text] [Related]
10. Thinking and acting beyond the positive: the role of the cognitive and negative symptoms in schizophrenia. Carbon M; Correll CU CNS Spectr; 2014 Dec; 19 Suppl 1():38-52; quiz 35-7, 53. PubMed ID: 25403863 [TBL] [Abstract][Full Text] [Related]
11. Social interaction and social withdrawal in rodents as readouts for investigating the negative symptoms of schizophrenia. Wilson CA; Koenig JI Eur Neuropsychopharmacol; 2014 May; 24(5):759-73. PubMed ID: 24342774 [TBL] [Abstract][Full Text] [Related]
12. Anhedonia, self-experience in schizophrenia, and implications for treatment. Juckel G; Sass L; Heinz A Pharmacopsychiatry; 2003 Nov; 36 Suppl 3():S176-80. PubMed ID: 14677076 [TBL] [Abstract][Full Text] [Related]
13. Genomics and epigenomics in novel schizophrenia drug discovery: translating animal models to clinical research and back. Bosia M; Pigoni A; Cavallaro R Expert Opin Drug Discov; 2015 Feb; 10(2):125-39. PubMed ID: 25345474 [TBL] [Abstract][Full Text] [Related]
14. Genetically modified mice related to schizophrenia and other psychoses: seeking phenotypic insights into the pathobiology and treatment of negative symptoms. O'Tuathaigh CM; Desbonnet L; Waddington JL Eur Neuropsychopharmacol; 2014 May; 24(5):800-21. PubMed ID: 24290531 [TBL] [Abstract][Full Text] [Related]
15. Animal models of schizophrenia for molecular and pharmacological intervention and potential candidate molecules. Mouri A; Nagai T; Ibi D; Yamada K Neurobiol Dis; 2013 May; 53():61-74. PubMed ID: 23142533 [TBL] [Abstract][Full Text] [Related]
16. Pick Your Model Wisely: Understanding the Negative Symptoms of Schizophrenia in Rodent Models. Yohn SE; Conn PJ ACS Chem Neurosci; 2019 Jan; 10(1):33-35. PubMed ID: 30346132 [TBL] [Abstract][Full Text] [Related]
17. Dissecting negative symptoms in schizophrenia: opportunities for translation into new treatments. Foussias G; Siddiqui I; Fervaha G; Agid O; Remington G J Psychopharmacol; 2015 Feb; 29(2):116-26. PubMed ID: 25516370 [TBL] [Abstract][Full Text] [Related]
18. Use of biomarkers in the discovery of novel anti-schizophrenia drugs. Mikkelsen JD; Thomsen MS; Hansen HH; Lichota J Drug Discov Today; 2010 Feb; 15(3-4):137-41. PubMed ID: 20036755 [TBL] [Abstract][Full Text] [Related]
19. Pharmacological treatment of schizophrenia: a critical review of the pharmacology and clinical effects of current and future therapeutic agents. Miyamoto S; Miyake N; Jarskog LF; Fleischhacker WW; Lieberman JA Mol Psychiatry; 2012 Dec; 17(12):1206-27. PubMed ID: 22584864 [TBL] [Abstract][Full Text] [Related]